Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood.
Carsten SchwarzThilo MüllerSusanne LauKirn ParasherDoris StaabUlrich WahnPublished in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2017)
Anti-IL-5 antibodies, which can be applied without substantial drug intolerances, are a new, safe, and effective treatment option for pediatric patients with hypereosinophilic syndrome.